35th week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220273690 | Edible Formulations Based on Active Ingredients and Arginine - The object of the present invention is the use of arginine and/or a salt thereof as a stabilizer of an acid active ingredient having a pKa of between 1 and 5 such as S-Adenosyl-L-methionine, and an edible formulation comprising an acid active ingredient, arginine and/or a pharmaceutically acceptable salt thereof, and at least one physiologically acceptable excipient. | 2022-09-01 |
20220273691 | MODULATORS OF HSD17B13 EXPRESSION - Methods, compounds, and compositions useful for inhibiting HSD expression are provided. Such compounds, compositions, and methods are useful for treating, preventing, or ameliorating a disease associated with HSD 17B 13. | 2022-09-01 |
20220273692 | THERAPEUTIC AGENT FOR NERVOUS SYSTEM DISEASE - An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B | 2022-09-01 |
20220273693 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF FORMULATING THE SAME - Provided herein are compositions and methods of reducing adduct formation. | 2022-09-01 |
20220273694 | COMPOSITIONS AND METHODS FOR DECREASING INTRAOCULAR PRESSURE - Provided herein are methods and compositions for decreasing intraocular pressure in a subject. Also provided are methods and compositions for treating or preventing glaucoma. | 2022-09-01 |
20220273695 | MCM FOR GENE THERAPY TO ACTIVATE WNT PATHWAY - The present disclosure is related to methods of stimulating bone formation for the purpose of improving bone repair, accelerating bone healing, and/or generating new bone in a local region with absent or diminished bone due to injury, disease, or defect, comprising administering a composition comprising β-catenin mRNA complex to the subject. | 2022-09-01 |
20220273696 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA - The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use The invention relates infer alio to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. | 2022-09-01 |
20220273697 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS - This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C. | 2022-09-01 |
20220273698 | MEDICINAL AND/OR PHARMACEUTICAL COMPOSITIONS FOR INTRAVESICAL INSTILLATION, PREPARATION AND USE THEREOF - The present invention relates to novel medicinal and/or pharmaceutical compositions indicated as composition A and composition B in liquid form for use as a medicinal composition or medicament for intravesical instillation, in the simultaneous local treatment of diseases of the urethra and/or the bladder, where compositions A and B are for use advantageously in the treatment of bladder pain syndrome (interstitial cystitis), in the urethra, and by replenishment of the GAG-layer on the inner surface of the bladder, further advantageously composition A is for use for local analgesic and anaesthetic treatment of the urethra and/or the bladder, and further advantageously the treatment of inflammation of the urethra and/or the bladder and preparation thereof. According to the use of the compositions of the subject matter of the invention, the treatment of the IC/BPS is implemented in two steps using first composition A and secondly composition B for intravesical instillation through the urethra. Osmolarity and pH of the compositions are also optimized. According to the subject matter of the invention composition A comprises the following components: Local anaesthetic, advantageously Lidocaine or adequate salt thereof, corticosteroid, advantageously dexamethasone-disodium-diphosphate or non-steroid anti-inflammatory agent, advantageously diclofenac salt, where furthermore advantageously the local anaesthetic and the non-steroid anti-inflammatory agent and advantageous forms thereof are embedded in liposome or further advantageously are composing complex with a complex composing agent; alkaline basic, advantageously sodium hydroxide; sterile distilled water; alkaline salt, advantageously sodium chloride. According to the subject matter of the invention, furthermore, composition B comprises the following components: Hyaluronic acid or adequate alkaline salt thereof, advantageously sodium-hyaluronate, alkaline salt of chondroitin sulfate, advantageously sodium-chondroitin-sulfate, heparin, advantageously sodium salt of heparin; alkaline basic, advantageously sodium hydroxide or sodium hydrogen carbonate, sterile distilled water, alkaline salt, advantageously sodium chloride and alkaline earth metal salt, advantageously calcium chloride. | 2022-09-01 |
20220273699 | OPHTHALMIC COMPOSITIONS WITH IMPROVED DESSICATION PROTECTION AND RETENTION - The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound. | 2022-09-01 |
20220273700 | POLYMERIC TREATMENT COMPOSITIONS - Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use. | 2022-09-01 |
20220273701 | TREATMENT FOR REDUCING ADVERSE EVENTS INCLUDING CHEMOTHERAPY DISCOMFORT AND OTHER CONDITIONS - This disclosure relates to treatments for reducing the side effects associated with treatment of a medication or drug, such as a chemotherapy medication, being experienced by a patient. This may be accomplished by administering to a patient taking the medication, a buffered aqueous liquid having a pH of about 10 to about 11.5. | 2022-09-01 |
20220273702 | HYDROGEN SULFIDE AND NITRIC OXIDE THERAPY FOR COVID-19 INFECTION - Therapeutics and methods of treating COVID-19 comprising in a patient comprising administering to the patient an effective dose of a pharmacologic composition containing a first therapeutic; wherein the first therapeutic is a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment the H2S donor is one of include diallyl trisulfide (DATS), diallyl disulfide (DADS), sodium sulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, a sulfinate, a sulfoxide, a persulfide, a polysulfide, and a sulfone. According to a further embodiment the pharmacologic composition further contains a second therapeutic, wherein the second therapeutic is a nitrite, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment wherein the nitrite is an inorganic nitrite. | 2022-09-01 |
20220273703 | NRF2 ACTIVATION FOR TREATMENT OF NEPHROGENIC DIABETES INSIPIDUS - Disclosed is a method for treating or preventing nephrogenic diabetes insipidus (NDI) in a subject that includes administering to the subject a therapeutically effective amount of a Nuclear factor-erythroid 2-related factor 2 (Nrf2) inducer, thereby treating or preventing the NDI in the subject. The Nrf2 inducer may be a fumarate, a nitro fatty acid, a bardoxolone or sulforaphane. Also disclosed is a pharmaceutical composition comprising (i) a Nuclear factor-crythroid 2-related factor 2 (Nrf2) inducer and (ii) lithium or a lithium salt. | 2022-09-01 |
20220273704 | Fogonazo Solution - “Rapid, corrective treatment for respiratory tract infections; using a safe ultra-low dose of a derivative of chlorine.” | 2022-09-01 |
20220273705 | Method for the Reduction of Dangerous Blood Sugar Levels - The present invention relates to a method and procedure for reducing immediate serum glucose levels without resort to drugs. Specifically, the invention discloses a regular regimen comprising modest exercise, daily nutritional supplements and a series of specific, time sensitive steps, which, when followed will optimize the effects of the invention. | 2022-09-01 |
20220273706 | Composition and Method for treatment of diabetes - Disclosed are a pharmaceutical use of a gold cluster for the treatment of diabetes in a subject. The gold cluster comprises a gold core and a ligand modifying the gold core. | 2022-09-01 |
20220273707 | COMPOSITIONS AND METHODS FOR TREATING CANINE PARVOVIRUS INFECTION - Provided herein are therapies that decrease the symptoms associated with Canine parvovirus infection, decrease time to recovery, and decrease the time infected dogs spend hospitalized in isolation. | 2022-09-01 |
20220273708 | FIBROUS CONSTRUCTS WITH THERAPEUTIC MATERIAL PARTICLES - Sheets of material used in medical devices and filters are disclosed. The sheets may include a fibrous mat including a plurality of microfibers. The microfibers may include a polymer matrix and a plurality of additive particles. The additive particles may include carbon material particles, therapeutic micro particles, and any combination thereof. Medical devices and filters that use the sheets are disclosed. Methods of producing the sheets are also disclosed. | 2022-09-01 |
20220273709 | DEVELOPMENT OF THERAPY FOR IMPROVING MYOCARDIAL CONTRACTION AND METHOD FOR INHIBITING CARDIOMYOCYTE DEATH - The present invention provides a pharmaceutical for preventing and/or treating non-ischemic cardiomyopathy, the pharmaceutical comprising dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide. | 2022-09-01 |
20220273710 | A CD79-SPECIFIC CHIMERIC ANTIGEN RECEPTOR - The present invention provides a chimeric antigen receptor (CAR) which specifically binds CD79. It further provides a nucleic acid sequence and a vector encoding said CAR. It further provides a cell which expresses said CAR at the cell surface. | 2022-09-01 |
20220273711 | Ultraspecific Cell Targeting Using De Novo Designed Co-Localization Dependent Protein Switches - Disclosed am protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called die key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain only when the protein switch components are co-localized when bound to their targets, components of such protein switches, and their use. | 2022-09-01 |
20220273712 | FOXP3 ENGINEERED CD4+ T CELLS FOR USE IN TREG-BASED IMMUNOTHERAPY - Engineered Treg-like cells, CD4 | 2022-09-01 |
20220273713 | METHOD OF INHIBITING OR ACTIVATING GAMMA DELTA T CELLS - The present disclosure relates to methods for inhibiting activation of γδ T cells that express a Vγ9+ TCR in a subject by administering a BTN2A1 antagonist to a subject as well as methods for inducing or enhancing γδ T cells that express a Vγ9+ TCR in a subject by administering a BTN2A1 antagonist to a subject. The disclosure additionally relates to BTN2A1 antagonists and BTN2A1 agonists. | 2022-09-01 |
20220273714 | T-CELL RECEPTORS AND METHODS OF USE THEREOF - The present disclosure relates to T-cell receptors (TCRs) and related antigen-binding constructs that selectively target a tumor-specific isoform of human RAD54 Homolog B (RAD 54B). Further disclosed are the antigen-binding constructs specific for binding the peptide in a peptide/MHC complex, as well as the sequences of complementary determining regions of the TCRs. | 2022-09-01 |
20220273715 | COMPOSITIONS AND METHODS FOR SEQUENTIAL STACKING OF NUCLEIC ACID SEQUENCES INTO A GENOMIC LOCUS - The present invention encompasses compositions and methods for the sequential stacking of donor nucleic acids into a single genomic locus within a cell to allow for the introduction of relatively long nucleic sequences. This allows for insertion into the genome of a donor nucleic acid sequence that exceeds the packaging capacity of a single adeno-associated viral vector. | 2022-09-01 |
20220273716 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CD38 CHIMERIC ANTIGEN RECEPTOR - Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) to the subject so as thereby to provide an effective treatment of the cancer in the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and lymphoma. The present invention also provides compositions comprising human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) or the treatment of multiple myeloma and lymphoma and methods of their use. | 2022-09-01 |
20220273717 | IMPROVED FORMULATIONS FOR IMMUNE CELLS - We disclose various improvements for compositions of T cells, including the use of lower levels of serum albumin and of cryoprotectants such as dimethyl sulfoxide. | 2022-09-01 |
20220273718 | BISPECIFIC ANTIBODY TARGETING OF T REGULATORY CELLS FOR TREATMENT OF INFLAMMATORY CONDITIONS - Provided are methods and compositions for treating disease and/or disorders associated with inflammatory conditions, such as autoimmune diseases, graft-vs-host diseases, and/or organ graft rejection (collectively AGO), In some embodiments, the methods include isolating peripheral blood mononuclear cells from a patient suffering from AGO, arming a population of T | 2022-09-01 |
20220273719 | GENETICALLY MODIFIED NK CELLS AND USES THEREOF - Disclosed herein include a natural killer (NK) cell genetically modified to comprise a recombinant nucleic acid encoding C-X-C Motif Chemokine Receptor 1 (CXCR1), a pharmaceutical composition comprising the NK cell, methods of preparing the NK cell, and method of treating cancer or tumor using the NK cell. | 2022-09-01 |
20220273720 | LYMPHODEPLETION DOSING REGIMENS FOR CELLULAR IMMUNOTHERAPIES - The present invention encompasses methods and compositions including genetically-modified cells expressing chimeric antigen receptors or exogenous T cell receptors, and pharmaceutical compositions thereof, for the treatment of cancer and other disorders and diseases. Further, provided herein are methods for depleting lymphocytes in a subject in need of treatment prior to, concomitant with, or following administration of the genetically-modified cells provided herein. | 2022-09-01 |
20220273721 | COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS - The disclosure provides immune cells comprising a first activator receptor and a second inhibitory receptor, and methods of making and using same for the treatment of cancer. | 2022-09-01 |
20220273722 | ANTI-EGFR/HIGH AFFINITY NK-CELLS COMPOSITIONS AND METHODS FOR CHORDOMA TREATMENT - Chordoma is treated in a patient by co-administration of an anti-EGFR antibody and high affinity NK cells (haNK). Most preferably, the antibody is non-covalently bound to a high affinity variant of a CD16 receptor or administered before transfusion of the haNK cells to so target the chordoma cells for cytotoxic cell killing by the haNK cells. | 2022-09-01 |
20220273723 | Immunocompetent Cell and Expression Vector Expressing Regulatory Factors of Immune Function - It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell. | 2022-09-01 |
20220273724 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTIPLATELET INDUCED COAGULOPATHY - Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein. | 2022-09-01 |
20220273725 | THERAPEUTIC DRUGS FOR FIBROSIS, INFLAMMATION, AND/OR AGING DISEASES - An object of the present invention is to provide a therapeutic agent and a preventive agent which exert a therapeutic effect on fibrotic diseases such as pulmonary fibrosis, inflammatory diseases and/or aging-associated diseases. Focusing on exosomes, the present inventors have repeatedly studied on the pathology and treatment methods of fibrotic diseases such as pulmonary fibrosis, inflammatory diseases, and aging-associated diseases, and as a result thereof, it was found that the exosomes derived from mesenchymal stem cells (MSC) have excellent therapeutic effects and/or preventive effects on the above diseases. Accordingly, the present invention relates to a therapeutic or prophylactic agent and a pharmaceutical composition comprising the therapeutic and/or prophylactic agent, which is a therapeutic or prophylactic agent for at least one of a fibrotic disease, an inflammatory disease, and an aging-associated disease, and comprises exosomes derived from mesenchymal stem cells. | 2022-09-01 |
20220273726 | TREATMENT OF NEURONAL DISEASES - The invention described herein provides methods and compositions for treating certain neurodegenerative diseases, such as RGC loss-related degenerative disease and Parkinson's Disease, using in vivo conversion of glial cells to neurons by PTB and optionally nPTB knock down via CRISPR/Cas delivered by viral vectors (e.g., AAV vector). | 2022-09-01 |
20220273727 | HOLLOW THREE-DIMENSIONAL UNIT MADE FROM RETINAL TISSUE AND USE THEREOF IN THE TREATMENT OF RETINOPATHIES - The invention relates to three-dimensional tissue units which are hollow and which comprise, when organized about an internal opening, at least one layer of living human retinal pigment epithelium cells which are differentiated, the basal face of each cell pointing outwards and the apical face pointing towards the internal opening. The invention also relates to these tissue units for use in the treatment of retinopathies, and to a method for preparing these tissue units and an implantation kit. | 2022-09-01 |
20220273728 | TREATING MYELIN DISEASES WITH OPTIMIZED CELL PREPARATIONS - The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells. | 2022-09-01 |
20220273729 | CDC-DERIVED EXOSOMES FOR TREATMENT OF VENTRICULAR TACHYARRYTHMIAS - Described herein are compositions and methods related to use of exosomes, including cardiosphere derived cell (CDC)-derived exosomes for treatment and prevention of heart related disease and conditions, such as ventral arrhythmias, such as tachycardias. CDC-derived exosomes delivered by endocardial injection can diminish the total amount of isolated late potentials associated with an isthmus of slow conduction, while reducing the isoelectric interval between late abnormal ventricular activity and decreasing the incidence of inducible ventricular arrhythmias, thereby providing a biological treatment for arrhythmias which otherwise requires therapeutic interventions with adverse effects. | 2022-09-01 |
20220273730 | Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors via Glucose-Dependent Viability - Provided is a nucleic acid system introduced into a bacterial strain to generate a genetically engineered bacterial strain that grows in solid tumors but does not grow in non-tumor tissues, the nucleic acid system comprising: a first DNA fragment that encodes a toxin gene that expresses a toxin that kills the genetically engineered bacterial strain; a second DNA fragment that encodes an antidote gene that expresses an antidote that negates the toxin; a first promotor that controls transcription of the antidote gene, such that glucose represses the transcription of the antidote gene; and a first constitutive promoter that causes constitutive expression of the toxin gene; wherein the second DNA fragment is transcribed in the solid tumors but not transcribed in the non-tumor tissues. | 2022-09-01 |
20220273731 | COMPOSITIONS AND METHODS OF TREATMENT OF CHRONIC INFECTIOUS DISEASES - In alternative embodiments, provided are novel applications of bacteria which originate from the phylum of | 2022-09-01 |
20220273732 | PROBIOTIC THERAPIES FOR SOCIAL DEFICIT AND STRESS RESPONSE - Some embodiments include bacterial species for use in treatment of social behavioral deficit symptoms in a subject in need thereof. The bacterial species can include | 2022-09-01 |
20220273733 | NUTRITIVE COMPOSITIONS WITH BIOACTIVE PROTEINS - The inventions described herein relate generally to compositions comprising bioactive proteins including, but not limited to, enzymes and antimicrobial proteins. Such bioactive protein compositions may be present alone or in a mammalian milk or soy-based nutritional product to increase colonization of desired commensal organisms, reduce potential pathogens, restore microbiome function, and/or otherwise improve health in a mammal consuming same. | 2022-09-01 |
20220273734 | METHODS FOR REDUCING PURINE CONTENT AND ALLEVIATING DISORDER OF URIC ACID METABOLISM - Disclosed herein are methods for reducing purine content in an edible material and alleviating a disorder of uric acid metabolism using | 2022-09-01 |
20220273735 | Composition Including Probiotics and Method of Increasing Amount of Oral Immunoglobulin A and Inhibiting Oral Pathogens by Administering the Same - The invention provides a method of increasing an amount of oral immunoglobulin A (IgA) and/or inhibiting oral pathogens in a subject in need thereof, which utilizes a composition including a therapeutically effective amount of probiotics as an effective ingredient. The probiotics include | 2022-09-01 |
20220273736 | METHODS OF DETECTING OVARIAN CANCER - The invention relates to a method of determining whether a subject is at an increased risk of developing or having ovarian cancer or being a carrier of a germline BRCA1 and/or BRCA2 mutation. The method may comprise determining whether the percentage contribution of lactic acid-producing bacteria to the bacterial load of a sample obtained from the lower genital tract of the subject is more or less than a percentage threshold level. The subject is at increased risk if the percentage contribution of lactic acid-producing bacteria to the bacterial load of the sample is less than the percentage threshold level. Alternatively, the method may comprise determining the pH of a sample obtained from the lower genital tract of the subject. The subject is at increased risk if the pH is higher than a pH threshold level. | 2022-09-01 |
20220273737 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKIN - The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa. | 2022-09-01 |
20220273738 | ONCOLYTIC VIRUS AND APPLICATION THEREOF, AND DRUG FOR TREATING CANCER - Provided are an oncolytic virus and an application thereof, and a drug for treating a cancer. A first regulatory element and a second regulatory element are inserted into the genome of the oncolytic virus. The first regulatory element comprises a tumor-specific promoter and a first nucleic acid sequence, which is driven by the cancer cell specific promoter to express a specific protease in tumor cells; the second regulatory element comprises a second nucleic acid sequence for encoding an extracellular secretion signal peptide and a third nucleic acid sequence for encoding a specific cleavage site. The oncolytic virus can be replicated in tumor cells effectively to kill tumor cells while being safe to non-cancer cells. | 2022-09-01 |
20220273739 | COMBINATION DRUG FOR TREATING MALIGNANT TUMOR, PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMOR, AND PHARMACEUTICAL COMPOSITION FOR MALIGNANT TUMOR TREATMENT - Provided are a combination drug for treating a malignant tumor, a pharmaceutical composition for treating a malignant tumor, and a pharmaceutical composition for malignant tumor treatment that have an exceptional antitumor effect. A malignant tumor can be treated by a combination drug containing a first medicine that includes an oncolytic virus belonging to the herpes simplex viruses type 1 as an active ingredient, and a second medicine that includes an interferon gene stimulating factor agonist as an active ingredient. | 2022-09-01 |
20220273740 | CHIMERIC VESICULOVIRUSES AND METHODS OF USE - The disclosure provides methods and materials for treating cancer. Specifically, the disclosure provides a chimeric vesiculovirus comprising: (a) a first genomic fragment of a first vesiculovirus species; and (b) a second genomic fragment of a second vesiculovirus species different from said first vesiculovirus species; wherein the vesiculovirus species comprising vesicular stomatitis viruses (VSVs) and morreton Virus (MorV). Further disclosed are methods of using chimeric vesiculoviruses as oncolytic agents for treating cancer. | 2022-09-01 |
20220273741 | NEW VIRUS PARTICLES FOR THERAPEUTIC PURPOSES - The invention relates to a virus particle comprising a lymphocytic choriomeningitis virus (LCMV) S segment and an LCMV L segment, wherein the S segment comprises an open reading frame encoding a glycoprotein derived from LCMV strain WE, and wherein the L segment comprises an open reading frame encoding an L protein derived from LCMV strain Clone13. The invention also relates to related host cells, methods of producing such virus particles, pharmaceutical compositions comprising such virus particles, and medical uses of such virus particles. | 2022-09-01 |
20220273742 | MATERIALS AND METHODS FOR BLOCKING MALARIA INFECTION AND TRANSMISSION - The subject invention provides fungal extracts, fungal metabolites, pharmaceutical compositions comprising the fungal extracts, and/or fungal metabolites, methods of preparation, and therapeutic uses thereof. The subject invention also provides a bioactive agent and a composition comprising the bioactive agent, and therapeutic uses thereof. The subject invention further provides methods for treating, inhibiting and/or preventing malaria infection and transmission by using the fungal extracts, fungal metabolites, bioactive agents, and pharmaceutical compositions comprising the fungal extracts, fungal metabolites, and/or bioactive agent. | 2022-09-01 |
20220273743 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF RESPIRATORY DISEASE - A composition for prevention, alleviation, or treatment of respiratory diseases, and a functional food and a pharmaceutical composition, each comprising same. There is also provided a composition for the enhancement of respiratory functions and the alleviation of respiratory diseases, comprising an | 2022-09-01 |
20220273744 | Process and Apparatus for Production of a Granular Cannabinoid Material Essentially Soluble in Aqueous Medium - A process and to an apparatus for production of a granular cannabinoid material essentially soluble in aqueous medium, wherein a matrix liquid composed of a first liquid that dissolves a cannabinoid or composed of a first liquid that dissolves a cannabinoid and a second liquid that forms an emulsion with the first liquid and a cannabinoid dissolved in the first liquid or emulsion is produced. The matrix liquid is dried by convection, and wherein the apparatus has a vessel system having an inlet and a matrix liquid outlet for production of the matrix liquid and a drying apparatus fluidically connected to the matrix liquid outlet of the vessel system. | 2022-09-01 |
20220273745 | MEDICINAL COMPOSITION OF AMARANTH ORIGIN FOR CARDIOVASCULAR TREATMENT - A medicinal composition having a nitrate enriched extract of Amaranth for the prevention and treatment of myocardial ischemia-reperfusion injury, and for the improvement of cardioprotective health and cardio renal protection. A method for the prevention and treatment of myocardial ischemia-reperfusion injury, method of improving cardioprotective health and cardio renal protection by using the composition having a nitrate enriched extract of Amaranth. | 2022-09-01 |
20220273746 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF ATOPIC DERMATITIS DISEASE - There is provided a composition for prevention, alleviation, or treatment of atopic dermatitis diseases, a functional food and a pharmaceutical composition, each including same, and a composition for alleviation of atopic dermatitis diseases, including an | 2022-09-01 |
20220273747 | NATURAL ESSENTIAL OIL COMPOSITION FOR RELAXING NERVES, SLEEPING WELL AND PREVENTING COLD AND FLU - The present invention provides a natural essential oil composition for relaxing nerves, sleeping well and preventing cold and flu. The composition comprises holy basil, lemongrass, patchouli, old coriander seeds, and tangerine peels, wherein the amount (wt %} of holy basil essential oil is about: 0.1% to about 60%; the amount (wt %) of lemongrass essential oil is about 0.1% to about 55; the amount (wt %) of patchouli essential oil is about 0.1% to about 30%; the amount: (wt %) of essential oil of old coriander seeds is about 0.1 to about 50% and the amount (wt %) of essential oil of tangerine peels is about 0.1% to about 50%. The composition of the present invention further comprises additional essential oils for further use purposes. The composition also comprises carrier oils and solvents for adjusting suit able concentrations of the composition. | 2022-09-01 |
20220273748 | PLANT FERMENT AND WEIGHT LOSS METHOD FOR USING THE SAME - Provided is a plant ferment, prepared by: mixing a mulberry ( | 2022-09-01 |
20220273749 | PLUM EXTRACT AND METHOD FOR IMPROVING PHYSICAL FUNCTION WITH THE SAME - Provided is a method for improving physical function, including administering to a subject in need thereof a composition including a plum extract extracted from unripe green plums that are harvested within two to three months after flowering. The plum extract is used for inhibiting accumulation of lipid droplets in cells, increasing a metabolic rate, improving gastrointestinal function, and reducing a weight and/or a waist circumference. | 2022-09-01 |
20220273751 | GPCR HETEROMER INHIBITORS AND USES THEREOF - This invention relates to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers (CXCR4-GPCR heteromers) associated with cancers, where CXCR4 forms a functional heteromer with other G protein-coupled receptors (GPCRx). More specifically, this invention relates to ADRB2 that form heteromers with CXCR4, which upon co-stimulation with CXCR4 agonists and ADRB2 agonists leads to enhanced signaling downstream of CXCR4. This invention also provides for pharmaceutical compositions and kits comprising a CXCR4 inhibitor and an ADRB2 inhibitor, and methods for treating and using the same, and in the diagnosis and/or therapy for cancer. | 2022-09-01 |
20220273752 | MODULATION OF DENDRITIC CELL FUNCTION BY THE PHOSPHOLIPID MESSENGER LPA - Described herein are compositions and methods that include use of PERK inhibitors, inhibitors of enzymes that can synthesize lysophosphatidic acid (LPA), inhibitors of LPA signaling, such as LPA receptor antagonists, deletion/mutation knockout/knock-down) or PERK or LPA receptors, or combinations thereof. Such compositions and methods can increase production of interferon by dendritic cells in subjects suffering from cancer and improve the survival of those subjects. | 2022-09-01 |
20220273753 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS - Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus. | 2022-09-01 |
20220273754 | SS-31 FOR THE PREVENTION AND/OR TREATMENT OF ANEURYSM - The present invention relates to SS-31 or composition comprising SS-31 for use in the treatment and/or prevention of aneurysm. | 2022-09-01 |
20220273755 | PHARMACEUTICAL COMPOSITION, USE AND METHOD FOR APPLYING GANODERMA MICROSPORUM IMMUNOMODULATORY PROTEIN AND KEYHOLE LIMPET HEMOCYANIN IN CARCINOMA TREATMENT - The invention provides a pharmaceutical composition. The pharmaceutical composition includes a | 2022-09-01 |
20220273756 | COMPOUNDS AND METHODS FOR INHIBITING PROTOZOAN PARASITES - Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liver-stage parasite development of a protozoan parasite, such as | 2022-09-01 |
20220273757 | METHODS FOR ADMINISTERING ANGIOTENSIN II BY MONITORING RENIN LEVELS - The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of hypotension. | 2022-09-01 |
20220273758 | TEVERELIX-TFA COMPOSITION - The present invention relates to a teverelix-TFA composition having a molar ratio of teverelix to trifluoroacetate composition of at least 1:2.2. Such a molar ratio will prevent undesirable gel-formation and provide a homogenous suspension, whereby a unique bioavailablity of teverelix is obtained. | 2022-09-01 |
20220273759 | PHARMACEUTICAL ASSOCIATION FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF - The present disclosure provides a pharmaceutical association for use in the treatment, prevention and/or diagnostic of a neoplastic disease, said association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one bioactive carrier forming at least one covalent or non-covalent interaction with said at least one growth factor receptor-binding compound, and wherein said association reduces or suppresses, in the neoplastic cell, the gene expression of at least one cyclin D and/or reduces or suppresses the formation of at least one complex formed between said at least one cyclin D and at least one of cyclin dependent-kinase 4 or 6. | 2022-09-01 |
20220273760 | A TEIXOBACTIN ANALOGUE AND USE THEREOF - Pharmaceuticals, and specifically a Teixobactin analogue and use thereof. A pharmaceutical composition having the compound and use of the compound and the pharmaceutical composition thereof inhibits the growth and/or reproduction of Gram-positive bacteria or | 2022-09-01 |
20220273761 | NUCLEIC ACID CONSTRUCT THAT ENCODES CHIMERIC RHODOPSIN - Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function. | 2022-09-01 |
20220273762 | GIP/GLP1 AGONIST COMPOSITIONS - A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided. | 2022-09-01 |
20220273763 | Treatment for Inflammatory Bowel Disease and Radiation-induced Intestinal Injury - Compositions for and methods of treating irritable bowel disease are provided. The compositions and methods employ MG53, which can be in the form of recombinant human MG53. The MG53 can be administered in a form to avoid or bypass gastric digestion or degradation. The composition can include a live MG53-expressing microbe, such as a probiotic composition that expresses MG53 in the gastrointestinal tract of a subject. An enteric release composition comprising MG53 is also provided. | 2022-09-01 |
20220273764 | Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders - The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization. | 2022-09-01 |
20220273765 | TOPICAL FORMULATION - The present invention concerns a composition comprising a peptide, a saccharide and a lipid vehicle, which is suitable for topical delivery. | 2022-09-01 |
20220273766 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF - Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing. | 2022-09-01 |
20220273767 | Interleukin 10 Conjugates and Uses Thereof - Disclosed herein are interleukin 10 (IL-10) conjugates and uses in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the IL-10 conjugates. | 2022-09-01 |
20220273769 | PHARMACEUTICAL COMPOSITION FOR TREATING LEVODOPA-INDUCED DYSKINESIA OR FOR SUP-PRESSING PROGRESSION THEREOF - A GLP-1 receptor agonist has effects of reducing serious side effects due to long-term use of levodopa when administered in combination with levodopa, and also effects of alleviating or improving abnormal involuntary movements (AIMs) caused by levodopa. A method for prevention or treatment of levodopa-induced dyskinesia according to an embodiment of the present disclosure includes administering a glucagon-like peptide-1 (GLP-1) receptor agonist to a patient. | 2022-09-01 |
20220273770 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES - Glucose-responsive insulin conjugates that contain one or more trisaccharides are provided. Such insulin conjugates may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule. | 2022-09-01 |
20220273771 | SYSTEMS, COMPOSITIONS AND METHODS FOR TREATING DIABETES - This disclosure provides methods for treatment comprising co-administering insulin and glucagon to a subject, and co-formulations comprising insulin and glucagon. | 2022-09-01 |
20220273772 | BIOENGINEERED FORMULATION, PROCESS FOR PREPARING AND IMPLEMENTATIONS THEREOF - The present disclosure discloses a bioengineered formulation comprising: (a) a modified collagen peptide having a molecular weight in the range of 20-80 kDa, and with a degree of substitution in the range of 20-75%; and (b) a modified hyaluronic acid having a molecular weight in the range of 10-100 kDa, and with a degree of substitution in the range of 20-75%. The present disclosure also discloses the bioengineered formulation comprising stem cells, or exosomes, or combinations thereof. Further, the process for preparing the bioengineered formulation is also disclosed therein. Moreover, the formulation comprising: a) exosomes selected from the group consisting of corneal stromal stem cell derived-exosomes, primed mesenchymal stem cell derived-exosomes, and naive mesenchymal stem cell derived-exosomes; and (b) a clinically approved eye drop formulation is also provided. | 2022-09-01 |
20220273773 | TARGETING THE GASTROINTESTINAL BARRIER TO TREAT AGE-RELATED DISORDERS - The disclosure provides various aspects and embodiments of methods of, and compositions for use in methods of, treating age-related physiological alterations (e.g., those associated with age-related diseases or disorders) and/or treating or delaying the onset of age-related frailty in a subject. The methods include administering an AP-based agent or composition (e.g., a bovine intestinal alkaline phosphatase). | 2022-09-01 |
20220273774 | PROPHYLACTIC PROTECTION AGAINST VIRAL INFECTIONS - The present disclosure provides methods for prophylactically treating a subject for viral infections comprising topically administering a ranpirnase composition. The disclosure also provides compositions that could be used for prophylactic treatment. | 2022-09-01 |
20220273775 | Methods for Treating CLN2 Disease in Pediatric Subjects - Provided herein are methods of treating Neuronal Ceroid Lipofuscinosis (CLN2) disease in a subject less than 3 years old. In exemplary embodiments, the method comprises administering to the subject a formulation comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) in an amount effective to treat the CLN2 disease in the subject. Also provided are methods of delaying the onset of CLN2 disease, or a symptom thereof, in a subject less than 3 years old. In exemplary embodiments, the method comprises administering to the subject a formulation comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) in an amount effective to delay the onset of the CLN2 disease or symptom in the subject. | 2022-09-01 |
20220273776 | Compositions and Methods for Treating Elevated Secretory Activity - Methods for treating diseases characterized by elevated secretory activity using a protease directed to a non-neuronal SNARE protein are described. The protease is produced by selective mutation of a | 2022-09-01 |
20220273777 | METHODS OF TREATING CELIAC DISEASE - Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Celiac disease. Also described herein is a method for treating a subject with Celiac disease using digestive enzymes and their derivatives to alleviate the symptoms of Celiac disease. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Celiac disease. | 2022-09-01 |
20220273778 | METHOD OF INDUCING ANTIGEN-SPECIFIC TOLERANCE IN A SUBJECT BY ADMINISTERING A COMPOSITION COMPRISING AN APOPTOTIC BODY SURROGATE AND COUPLED IMMUNODOMINANT ANTIGENIC EPITOPES ASSOCIATED WITH AUTOIMMUNE DISEASE - The present invention provides compositions and methods for inducing antigen-specific tolerance in a subject. In one embodiment, the present invention provides a composition comprising an apoptotic body and an epitope of an antigen. Also provided herein are methods of preparing and administering the composition. The composition and methods provided herein can induce antigen-specific tolerance in a subject. | 2022-09-01 |
20220273779 | TAU PEPTIDE ANTIGENS AND ANTIBODIES BINDING THERETO FOR THE TREATMENT OF TAUOPATHIES - The disclosure provides methods and compositions for treating and diagnosing tauopathies. More specifically, the disclosure relates to the identification of epitopes on tau and their use as vaccines or as reagents to generate monoclonal antibodies that can be used for both diagnosis and treatment of tau-related diseases. | 2022-09-01 |
20220273780 | SELF-ASSEMBLED VACCINES AND COMBINATION THERAPIES FOR TREATING CANCER - Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to a biotinylated component (e.g., tumor cell, tumor antigen, virus or viral antigen). The self-assembling pharmaceutical compositions may further comprise an immunotherapy (e.g., anti-PD-1 antibody). In addition, methods of using these pharmaceutical compositions to prevent and/or treat cancer, or to induce an immune response are provided. Methods of using the self-assembling pharmaceutical compositions in combination with an immunotherapy (e.g., anti-PD-1 antibody) are also provided. | 2022-09-01 |
20220273781 | POLYPEPTIDES FOR TREATMENT OF AML - The present invention relates to a polypeptide comprising (i) a binding peptide binding to at least one surface marker of an acute myeloid leukemia (AML) cell, and (ii) an immunogenic peptide comprising at least one T-cell epitope; and to means and methods related thereto. | 2022-09-01 |
20220273782 | Novel PD-L1 Targeting DNA Vaccine for Cancer Immunotherapy - The present invention relates to an attenuated strain of | 2022-09-01 |
20220273783 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-09-01 |
20220273784 | Methods and compositions for liquidation of tumors - This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors wherever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to liquidation of tumors. The method includes administering priming doses of the therapeutic composition, ablation of a selected tumor lesion along with intratumoral injection of the composition and then infusion of the therapeutic composition. These steps enable the systemic liquidation of tumors secondary to immune cell infiltration and leads to immune-mediated tumor eradication. | 2022-09-01 |
20220273785 | MODIFIED BRUCELLA VACCINE STRAIN FOR THE TREATMENT OF BRUCELLOSIS - The present application provides a modified | 2022-09-01 |
20220273786 | ZIKA VIRUS VACCINE - Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof. | 2022-09-01 |
20220273787 | CO-ADMINISTRATION OF SEASONAL INFLUENZA VACCINE AND AN ADENOVIRUS BASED RESPIRATORY SYNCYTIAL VIRUS VACCINE - Methods of inducing a protective immune response against respiratory syncytial virus (RSV) and against influenza virus, without inducing a severe adverse event in human subjects are described. The methods include administering to the subjects an effective amount of an adenoviral vector encoding a recombinant RSV F polypeptide that is stabilized in a pre-fusion conformation, along with an effective amount of an influenza vaccine. | 2022-09-01 |
20220273788 | VACCINE - The present invention provides an African swine fever virus (ASFV) subunit vaccine which comprises: (i) one or more recombinant polynucleotides which encode polypeptides shown as SEQ ID NO: 1, 2 and 3 or an immunogenic fragment thereof; or a variant with at least 70% sequence identity to one of SEQ ID NO: 1, 2 or 3; wherein the total number of different ASFV polypeptides encoded by the one or more recombinant polynucleotides is 10 or fewer; or (ii) recombinant polypeptides shown as SEQ ID NO: 1, 2 and 3 or an immunogenic fragment thereof; or a variant with at least 70% sequence identity to one of SEQ ID NO: 1, 2 and 3; wherein vaccine comprises 10 or fewer different ASFV polypeptides. | 2022-09-01 |
20220273789 | THERAPEUTIC VIRAL VACCINE - The present invention relates to viral Fc receptor or immunogenic fragments thereof for treating a viral infection in a subject and, in particular, a herpes vims infection. The present invention also relates to a heterodimer comprising or consisting of an Fc receptor from a HSV vims or an immunogenic fragment thereof and a binding partner from said HSV vims or a fragment thereof, for use in therapy. | 2022-09-01 |
20220273790 | RATIONALLY ENGINEERED CARRIER PROTEINS FOR VACCINES - The invention relates to the design of rationally engineered Carrier Proteins (reCaPs) geared towards producing Multifunctional Chimeric recombinant Fusion Proteins (MCFPs) useful as vaccine candidates. The key components of the MCFPs are (i) genetically engineered carrier proteins; (ii) polypeptide antigens; (iii) linker peptides, optionally fused to heterologous T-cell epitopes; (iv) Dual Function Peptides (DFP) which can act as a purification aids as well having the non-covalent affinity to bind to an adjuvant. The present invention also relates to recombinantly expressed Self-Assembling Adjuvanted Nanoparticles (SAANPs), comprising reCaPs fused with various polypeptide and protein antigens, useful as vaccine candidates. The present invention also provides novel ‘integrated Multiple Conjugate Antigen displayed Adjuvanted Systems’ [iMCAAS], comprising rationally engineered Carrier Proteins, based on ‘Self Assembling Adjuvanted Nanoparticles’ [SAANPs]. These adjuvanted nanoparticles, eventually provide stronger antigen-antibody interactions compared to the low affinity interactions provided by the monovalent binding generated by single antigen immunogens. | 2022-09-01 |
20220273791 | SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION - The invention relates to a pharmaceutical composition for the modulation of T cell and B cell responses made of one or more prepatations and comprising a therapeutically effective dose of at least one inhibitor of TNFR1-mediated functions and of at least one antigen or allergen. | 2022-09-01 |